Department of Clinical Sciences Malmö, SciLifeLab, Lund University, Lund, Sweden.
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden; Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden; Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
Cell Rep Med. 2024 Sep 17;5(9):101735. doi: 10.1016/j.xcrm.2024.101735.
Alzheimer's disease (AD) is the most common neurodegenerative disease and is characterized by the aggregation of β-amyloid (Aβ) and tau in the brain. Breakthroughs in disease-modifying treatments targeting Aβ bring new hope for the management of AD. But to effectively modify and someday even prevent AD, a better understanding is needed of the biological mechanisms that underlie and link Aβ and tau in AD. Developments of high-throughput omics, including genomics, proteomics, and transcriptomics, together with molecular imaging of Aβ and tau with positron emission tomography (PET), allow us to discover and understand the biological pathways that regulate the aggregation and spread of Aβ and tau in living humans. The field of integrated omics and PET studies of Aβ and tau in AD is growing rapidly. We here provide an update of this field, both in terms of biological insights and in terms of future clinical implications of integrated omics-molecular imaging studies.
阿尔茨海默病（AD）是最常见的神经退行性疾病，其特征是大脑中β-淀粉样蛋白（Aβ）和 tau 的聚集。针对 Aβ 的疾病修饰治疗的突破为 AD 的治疗带来了新的希望。但是，为了有效地修饰并最终预防 AD，需要更好地了解潜在的生物学机制，这些机制将 Aβ 和 tau 在 AD 中联系起来。包括基因组学、蛋白质组学和转录组学在内的高通量组学的发展，以及正电子发射断层扫描（PET）对 Aβ 和 tau 的分子成像，使我们能够发现和理解调节 Aβ 和 tau 在活体内聚集和传播的生物学途径。AD 中 Aβ 和 tau 的整合组学和 PET 研究领域正在迅速发展。我们在这里提供该领域的最新进展，包括生物学见解以及整合组学-分子成像研究的未来临床意义。
